The production of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, represents a complex multi-step synthetic process. Early routes focused on peptide portion coupling, utilizing solid-phase synthesis methodologies to build the long protein sequence. Subsequent investigation has explored alternative approaches, including enz